The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management

Sapone, Andrea; Vaira, Dino; Trespidi, Silvia; Perna, Federico; Gatta, Luigi; Tampieri, Andrea; Ricci, Chiara; Cantelli‐Forti, Giorgio; Miglioli, M.; Biagi, Giacomo; Paolini, Moreno

doi:10.1111/j.1572-0241.2003.07427.x

Cited by 69 publications

(21 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies on Kawabata et al, 2003), whereas others show lower cure rates in homozygous EMs (ϳ60 versus Ͼ90% in the other groups) (Furuta et al, 2001a;Inaba et al, 2002). Almost all of the studies of H. pylori eradication have been undertaken in Japanese patients, although available data in Caucasians suggest similar findings (Sapone et al, 2003;Schwab et al, 2004;Gawronska-Szklarz et al, 2005). It seems that genotyping could provide a useful aid to prescribing for H. pylori eradication, and initial data suggest that this effort may be cost-effective (Lehmann et al, 2003).…”

Section: Drugmentioning

confidence: 79%

“…Overall, omeprazole and lansoprazole-based regimens produce lower eradication rates in homozygous EMs than in heterozygous EMs or PMs (Furuta et al, 2001b;Sapone et al, 2003). For example, a 7-day triple therapy regimen resulted in cure rates of 60% in homozygous EMs, compared with 84 and 100% of heterozygous EMs and PMs, respectively (Sapone et al, 2003).…”

Section: Drugmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

2006

View full text Add to dashboard Cite

Section: Drugmentioning

confidence: 79%

Section: Drugmentioning

confidence: 99%

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

2006

View full text Add to dashboard Cite

“…CYP3A4 and IL1B -511 polymorphisms are also shown to have effects on eradication rates 45,46 . Moreover, absorption of orally dosed drugs is often influenced by an ATP-dependent efflux transporter, P-glycoprotein (P-gp).…”

Section: Host Factors Influencing Treatment Successmentioning

confidence: 99%

New concepts of resistance in the treatment of Helicobacter pylori infections

Graham

Shiotani

2008

Nat Rev Gastroenterol Hepatol

312

368

View full text Add to dashboard Cite

SummaryThe prevalence of antimicrobial resistance is now such that all patients should be considered as having resistant infections. Ideally therapy is based on pretreatment susceptibility testing. Empiric therapies should assume antimicrobial resistance and use higher doses for 14 days. Acceptable results are 90-94% cure intention to treat (Grade B) or greater. Clarithromycin-containing triple therapies now typically produce ≤80% cure ITT (Grade F) and are no longer acceptable empiric therapy. Current initial therapy options are between sequential therapy, concomitant therapy, and bismuth containing quadruple therapy. Sequential therapy has the potential to be improved to ≥95% cure ITT (Grade A) by continuing the amoxicillin through the second and/or by increasing the duration. Better appreciation of the role of acidity in phenotypic resistance has resulted in high cure rates with high dose PPI plus amoxicillin dual therapy; additional studies to devise better dual-based multidrug regimes are still needed. Antimicrobial choices following treatment failure is best approached by susceptibility testing. If not available, we recommended a bismuth containing quadruple therapy substituting a new drug for metronidazole/tinidazole and/or clarithromycin if they have been used previously. The alternate would be to use a 14 day high dose PPI, amoxicillin-based triple therapy with rifabutin, a fluoroquinolone, or furazolidone. KeywordsHelicobacter pylori; therapy; resistance; antibiotics; anti-secretory drugs; phenotypic drug resistance; cytochrome P450 "To read without reflecting is like eating without digesting". -86-462-1111-86-462- , FAX 81-86-464-1195 Review criteria: We searched the relevant papers by using computer-assisted bibliographic searches of PubMed through November 30, 2007 using combinations of the following terms: H. pylori combined with resistance, therapy, eradication, second, triple, quadruple, sequential, or rescue. We also reviewed the recent literature on pharmacokinetics and pharmacodynamics in relation to the drugs used in H. pylori therapy and the relation to host cytochrome P450 genotypes to treatment outcome. We did not perform meta-analyses. We reviewed only articles published in English.

show abstract

“…Based on the generally accepted idea that therapeutic efficiency of omeprazole is influenced by the CYP2C19 genotype, some authors have suggested that this also affects the effectiveness of different PPIs. However, the less clear influence of the CYP2C19 genotype over further PPIs, support that this relationship actually depends on the kind of PPI (Chang et al, 1995;Sapone et al, 2003).…”

Section: Cyp2c19 Genotype Frequenciesmentioning

confidence: 99%

Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico

Salazar-Flores

Torres-Reyes

Martínez-Cortés

et al. 2012

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Background: The distribution of polymorphisms in the CYP2D6 and CYP2C19 genes allows inferring the potential risk for specific adverse drug reactions and lack of therapeutic effects in humans. This variability shows differences among human populations. The aim of this study was to analyze single-nucleotide polymorphisms related to a poor metabolizer (PM) phenotype in nonpreviously studied Amerindian groups and Mestizos (general admixed population) from Mexico. Methods: We detected by SNaPshot Ò different polymorphisms located in CYP2D6 (*3, *4, *6, *7, and *8) and CYP2C19 (*2, *3, *4 and *5) in western Mestizos (n = 145) and five Amerindian groups from Mexico: Tarahumaras from the North (n = 88); Purépechas from the Center (n = 101); and Tojolabales (n = 68), Tzotziles (n = 88), and Tzeltales (n = 20) from the Southeast. Genotypes were observed by capillary electrophoresis. The genetic relationships among these populations were estimated based on these genes. Results and Discussion: The wild-type allele (*1) of both genes was predominant in the Mexican populations studied. The most widely observed alleles were CYP2C19*2 (range, 0%-31%) and CYP2D6*4 (range, 1.2%-7

show abstract

The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management

Cited by 69 publications

References 19 publications

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

New concepts of resistance in the treatment of Helicobacter pylori infections

Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico

Contact Info

Product

Resources

About